Groundbreaking HostDx Tests

The Inflammatix HostDx diagnostics are powered by ‘reading’ the immune system instead of looking for a bug. Our immune system has developed targeted responses to different types of infections and other diseases over millions of years of evolution.  We are initially launching HostDx Sepsis and HostDx Fever for better acute infection and sepsis diagnosis based on patent-pending biomarkers exclusively licensed from Stanford University.

HostDx Sepsis

Shooting for the holy grail:  Identify the presence, type and severity of an acute infection.

Tailored for emergency rooms. urgent care clinics and inpatient use to diagnose (or rule out) acute infection and sepsis in multiple clinical scenarios:

  • First presentation in the ED or urgent care clinic
  • Identifying infections in traumatic injuries
  • Neonate and ICU patient monitoring

Validation study results for the HostDx Sepsis test:  

Indication Sensitivity Specificity
Bacterial Infection 94% 60%
Viral Infection 53% 91%
30-day mortality (sepsis) 95% 64%
HostDx Sepsis Non-Flu Season Flu Season
Infection Type Estimated Prevalence NPV PPV Estimated Prevalence NPV PPV
Bacterial Infection 30% 96% 50% 15% 99% 30%
Viral Infection 50% 66% 86% 75% 40% 95%
Sepsis 25% 98% 47% 20% 98% 40%

Sweeney TE, Wong HR, Khatri P. “Robust classification of bacterial and viral infections via integrated host gene expression diagnostics.” Science Translational Medicine, Jul 6 2016.
Sweeney TE, Khatri P, et al. A community approach to mortality prediction in sepsis via gene expression analysis. Nature Communications 2018(9): 694. DOI: 10.1038/s41467-018-03078-2.

SEE MORE EVIDENCE

Where Are We Now?

We are in the process of fitting our HostDx assays onto novel diagnostic instruments with ideal product-market fit. Then, we will execute clinical studies required for regulatory clearance across the globe.

Scour appropriate cohorts in public and private datasets (raw gene expression and clinical data) to identify optimal genes and develop algorithms

Apply locked algorithms on multiple independent (blinded) public and private data sets (also with raw gene expression and clinical data)

Develop assays (wet lab) based on locked set of genes and algorithms and onboard onto novel rapid point-of-care instrument

Validate assay locked on instrument in independent (blinded) and representative clinical studies

Attain regulatory clearance (e.g. CE, 510K) and launch HostDx tests to clinics and hospitals globally

HostDx Fever

Soon, we’ll answer your simple question: Is my infection bacterial or viral?

Ideal for outpatient clinics and urgent care centers

Safely and confidently avoid prescribing antibiotics on negative results (multiple validation studies indicate that the HostDx Fever test can achieve a greater than 95% negative predictive value for bacterial infection )

HostDx fever

Validation study results for the HostDx Fever test

(bacterial infection as the “case” and viral infection as the “control”):

Indication Sensitivity Specificity
Bacterial Infection 96% 76%
HostDx Fever Non-Flu Season Flu Season
Infection Type Estimated Prevalence NPV PPV Estimated Prevalence NPV PPV
Bacterial Infection 35% Bacterial / 65% Viral 97% 69% 20% Bacterial / 80% Viral 99% 50%

Sweeney TE, Wong HR, Khatri P. “Robust classification of bacterial and viral infections via integrated host gene expression diagnostics.” Science Translational Medicine, Jul 6 2016.

SEE MORE EVIDENCE

Deep pipeline of novel, rapid HostDx™ tests

All new indications run on our <25 min POC platform

Stay in touch with Twitter updates: Find out the latest news.

Connect with Twitter